Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Belzutifan Beats Everolimus in Renal Cell Carcinoma
TOPLINE: Belzutifan demonstrated a significant benefit over everolimus in progression-free survival and objective response rates in advanced renal cell carcinoma. At 18 months, 24% of participants on belzutifan were alive and progression-free compared with 8.3% on everolimus. METHODOLOGY: The phase…
English